Deborah Andrews Net Worth

The estimated Net Worth of Deborah J Andrews is at least $801 Tausend dollars as of 29 June 2021. Ms. Andrews owns over 24,720 units of Lineage Cell Therapeutics Inc stock worth over $30,040 and over the last 19 years she sold LCTX stock worth over $771,333. In addition, she makes $0 as Independent Director at Lineage Cell Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Andrews LCTX stock SEC Form 4 insiders trading

Deborah has made over 22 trades of the Lineage Cell Therapeutics Inc stock since 2006, according to the Form 4 filled with the SEC. Most recently she exercised 24,720 units of LCTX stock worth $54,384 on 29 June 2021.

The largest trade she's ever made was exercising 106,604 units of Lineage Cell Therapeutics Inc stock on 21 January 2020 worth over $1,184,370. On average, Deborah trades about 6,921 units every 108 days since 2005. As of 29 June 2021 she still owns at least 34,720 units of Lineage Cell Therapeutics Inc stock.

You can see the complete history of Ms. Andrews stock trades at the bottom of the page.

Deborah Andrews biography

Deborah J. Andrews serves as Independent Director of the Company. Ms. Andrews has served as Chief Financial Officer of STAAR Surgical Company (STAA), a leader in the development, manufacture, and marketing of minimally invasive ophthalmic products employing proprietary technologies, since September 2017 after serving as Vice President, Chief Accounting Officer since 2013. Ms. Andrews also served as STAAR Surgical’s Vice President, Chief Financial Officer from 2005 to 2013, as its Global Controller from 2001 to 2005, and as its Vice President, International Finance from 1999 to 2001. Ms. Andrews previously worked as a senior accountant for a major public accounting firm. Ms. Andrews holds a B.S. degree in accounting from California State University at San Bernardino. Ms. Andrews brings to our Board significant experience in finance, financial reporting, accounting and auditing, and in management as a senior financial and accounting executive of a public medical device company during a period of significant growth.

How old is Deborah Andrews?

Deborah Andrews is 62, she's been the Independent Director of Lineage Cell Therapeutics Inc since 2014. There are 5 older and 11 younger executives at Lineage Cell Therapeutics Inc. The oldest executive at Lineage Cell Therapeutics Inc is Alfred Kingsley, 77, who is the Chairman of the Board.

What's Deborah Andrews's mailing address?

Deborah's mailing address filed with the SEC is C/O LINEAGE CELL THERAPEUTICS, 2173 SALK AVENUE, SUITE 200, CARLSBAD, CA, 92008.

Insiders trading at Lineage Cell Therapeutics Inc

Over the last 5 years, insiders at Lineage Cell Therapeutics Inc have traded over $2,612,743 worth of Lineage Cell Therapeutics Inc stock and bought 7,879,334 units worth $8,569,904 . The most active insiders traders include Partners, L.P.Broadwood Cap..., Alfred D Kingsley und Brian M Culley. On average, Lineage Cell Therapeutics Inc executives and independent directors trade stock every 49 days with the average trade being worth of $212,992. The most recent stock trade was executed by Jill Ann Howe on 16 August 2024, trading 10,500 units of LCTX stock currently worth $9,345.

What does Lineage Cell Therapeutics Inc do?

biotime, inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world's premier collection of pluripotent cell assets. the foundation of our core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.

Complete history of Ms. Andrews stock trades at Staar Surgical Co und Lineage Cell Therapeutics Inc

Lineage Cell Therapeutics Inc executives and stock owners

Lineage Cell Therapeutics Inc executives and other stock owners filed with the SEC include:

• Brandi Roberts,
  Chief Financial Officer
• Brian M. Culley M.A., M.B.A.,
  CEO, Pres & Director
• Brian Culley,
  Chief Executive Officer, Director
• Chase Leavitt,
  General Counsel and Corporate Secretary
• Brandi L. Roberts,
  Consultant
• Angus Russell,
  Independent Director
• Michael Mulroy,
  Independent Director
• Stephen Farrell,
  Independent Director
• Neal Bradsher,
  Independent Director
• Don Bailey,
  Independent Director
• Deborah Andrews,
  Independent Director
• Gary Hogge,
  Senior Vice President of Clinical & Medical Affairs
• Alfred Kingsley,
  Chairman of the Board
• Alexandra Hernandez,
  Sr. Director of Fin. & Controller
• Dr. Rami Skaliter,
  Chief Exec. Officer of Cell Cure Neurosciences Ltd.
• William Annett,
  Pres & CEO of OncoCyte Corp.
• Dr. Gary S. Hogge D.V.M., Dvm, Ms, Ph.D.,
  Sr. VP of Clinical & Medical Affairs
• Dr. François Binette M.Sc., Ph.D.,
  Sr. VP & Global Head of R&D
• George A. Samuel III, J.D.,
  Gen. Counsel & Company Sec.
• Ioana C. Hone,
  Director of Investor Relations
• Kevin L. Cook,
  Chief Financial Officer
• George A. Iii Samuel,
  General Counsel/Secretary
• Anula Jayasuriya,
  
• Dipti Amin,
  
• Neal C Bradsher,
  Director
• Alexandra Hernandez,
  Sr Director Finance/Controller
• Kevin Leon Cook,
  Chief Financial Officer
• Jill Ann Howe,
  Chief Financial Officer